Clinic Owners Faced Extradition Over Fraud Charges
Authorities allege the pair distributed unapproved and expired cancer drugs to patients in California and Arizona.
Updated on Sept. 28, 2026 in Cancer
Live Poll
Should government agencies enforce stricter oversight on the origins of prescription drugs?
Sukhi Ghuman and Kiranjit Ghuman are appearing at Westminster Magistrates' Court for a five-day extradition hearing. The United States government seeks the pair on charges of healthcare fraud and drug smuggling related to their past management of oncology clinics.
Why it matters
The case highlights the dangers of medical fraud, where patients unknowingly received unapproved or out-of-date treatments instead of regulated care. The investigation alleges the clinic owners prioritized profit by sourcing cheaper, unauthorized medications from overseas.
Federal investigators examined clinic operations between September 2019 and April 2023, identifying the use of unapproved and potentially expired cancer medications. These findings support ongoing criminal charges in the United States.
The players
Sukhi Ghuman
Clinic operator accused of defrauding Medicare and supplying unapproved drugs.
Kiranjit Ghuman
Clinic operator facing extradition on charges of drug smuggling and healthcare fraud.
The details
The defendants allegedly exploited the price difference between FDA-approved treatments and cheaper, unapproved alternatives imported from abroad. By administering these substances within their California and Arizona clinics, the operators reportedly exposed patients to clinical risks associated with unauthorized medical supply chains. Investigators uncovered these practices during a multi-year review of clinic records and procurement invoices.
Timeline
September 2019 to April 2023: Period of alleged fraudulent drug procurement and distribution.
October 2023: Arrest warrant issued for the pair in the Southern District of California.
September 2026: The extradition hearing begins at Westminster Magistrates' Court.
Health Landscape
This case marks an enforcement action against the bypass of pharmaceutical supply chains in the oncology sector. It underscores the importance of maintaining strictly regulated drug procurement protocols to ensure the safety and efficacy of patient treatments.
Patients are encouraged to verify that their oncology treatments are sourced from authorized, FDA-regulated pharmacies. If you have concerns about the origin or administration of your medications, discuss them directly with your prescribing physician.
The takeaway
This case serves as a reminder to be aware of the integrity of your medical care and treatment sourcing. Always feel empowered to ask your healthcare team about the source of any prescribed medication or administered therapy.
What happens next
The extradition hearing is scheduled to continue for a total of five days.
Further reading
For more on the risks of unregulated medical supply chains, visit Cancer.
Live Poll
Should government agencies enforce stricter oversight on the origins of prescription drugs?
